AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the ...

in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for high-risk non-muscle-invasive bladder cancer (NMIBC). The trial demonstrated a statistically significant ...

Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

Research and development expenses for the first quarter of 2025 increased to $9.1 million from $7.7 million for the prior ...